The last decade has seen numerous outbreaks of Clostridium difficile-associated disease (CDAD), which presented significant challenges for healthcare facilities worldwide. We have identified and purified thuricin CD, a two-component antimicrobial that shows activity against C. difficile in the nanomolar range. Thuricin CD is produced by Bacillus thuringiensis DPC 6431, a bacterial strain isolated from a human fecal sample, and it consists of two distinct peptides, Trn-α and Trn-β, that act synergistically to kill a wide range of clinical C. difficile isolates, including ribotypes commonly associated with CDAD (e.g., ribotype 027). However, this bacteriocin thuricin CD has little impact on most other genera, including many gastrointestinal commensals. Complete amino acid sequencing using infusion tandem mass spectrometry indicated that each peptide is posttranslationally modified at its respective 21st, 25th, and 28th residues. Solution NMR studies on [ 13 C, 15 N] Trn-α and [ 13 C, 15 N]Trn-β were used to characterize these modifications. Analysis of multidimensional NOESY data shows that specific cysteines are linked to the α-carbons of the modified residues, forming three sulfur to α-carbon bridges. Complete sequencing of the thuricin CD gene cluster revealed genes capable of encoding two S′-adenosylmethionine proteins that are characteristically associated with unusual posttranslational modifications. Thuricin CD is a two-component antimicrobial peptide system with sulfur to α-carbon linkages, and it may have potential as a targeted therapy in the treatment of CDAD while also reducing collateral impact on the commensal flora.
two-component bacteriocin | posttranslational modifications | Clostridium difficile-associated disease | peptide | NMR W ith the upsurge in antibiotic resistance among pathogens and the increase in hospital-acquired infections such as methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile, there is a pressing need to find novel antimicrobial compounds to combat these diseases. C. difficile was recognized as a causative agent of nosocomial diarrhea in the 1970s (1) , and is now a common occurrence, and cases of Clostridium difficile-associated disease (CDAD) are increasing both in numbers and severity in many parts of the world (2, 3) . The main predisposing factor for CDAD is antibiotic therapy, which often eradicates beneficial flora in the gut and allows C. difficile to flourish. Many antibiotics have been implicated in CDAD, including clindamycin, ampicillin, and amoxicillin as well as the cephalosporins and flouroquinolones (4-6). The increasing prevalence of the hypervirulent strain of C. difficile (PCR ribotype 027) (5, 7) adds urgency to the search for alternative treatments for CDAD. Thus far, small-molecule antibiotics have generally proven unsuccessful in mitigating the development of resistance in bacterial pathogens, indicating a need to examine alternative classes of antimicrobial compounds.
In this regard, there has been considerable interest in bacteriocins, antimicrobial peptides produced by bacteria that can have either narrow-or broad-spectrum antimicrobial activity. Nisin, a bacteriocin produced by Lactococcus lactis subsp. lactis that is used commercially in food preservation, has a broad spectrum of activity against other lactic acid bacteria (LAB) and most Gram-positive organisms (8) . Although bacteriocins produced by LAB are the most widely investigated (9, 10), bacteriocins are also produced by most other Gram-positive (11) (12) (13) (14) (15) and Gram-negative (16, 17) bacterial species.
Previous reports have shown that bacteriocins such as nisin and lacticin 3147 are effective in killing C. difficile at concentrations that compare favorably with vancomycin and metronidazolethe most commonly used antibiotics in the treatment of CDAD (18, 19) . Nisin and lacticin 3147 are broad-spectrum antimicrobials impacting on most Gram-positive species, including those that would be considered beneficial to human gut health such as Lactobacillus and Bifidobacterium. Indeed, previous work has shown that lacticin 3147 reduces the levels of Lactobacillus and Bifidobacterium in a fecal-based environment (18) . Therefore, we sought to isolate narrow-spectrum anti-C. difficile bacteriocins originating from the gut microbiota that would facilitate the elimination of the pathogen, while reducing the impact on the commensal flora. Herein, we report the isolation and purification of thuricin CD, a highly active anti-C. difficile agent produced by a bacterial strain derived from a human fecal sample. Through genetic and peptide sequencing, tandem mass spectrometry, and solution NMR studies, we have determined that thuricin CD contains unique posttranslational modifications that are unprecedented among two-peptide bacteriocin systems.
Results
Initial Screening for Bacteriocin Producers. Our goal was to isolate a narrow-spectrum bacteriocin effective against C. difficile that would not impact on beneficial Gram-positive flora in the intestine. We hypothesized that spore-forming anaerobic bacteria from the gut may be a likely source of bacteriocins active against a related bacterium like C. difficile. Spores were selected by including an ethanol wash step of human fecal samples to kill vegetative cells before plating. Using this approach, over 30,000 isolates were screened from fecal samples acquired from both healthy and diseased adults. Only one colony that was isolated produced a large zone in a C. difficile overlay culture (Fig. 1A) . The colony was purified and grown in brain-heart infusion (BHI) broth, and it was confirmed that a potent antimicrobial compound was produced and secreted into the growth medium. The
Author contributions: J.C.V., R.P.R., and C.H. designed research; M.C.R., C.S.S., E.C., P.M.O., and R.M.W. performed research; M.C.R., C.S.S., E.C., P.M.O., R.M.W., J.Z., J.C.V., R.P.R., and C.H. analyzed data; and M.C.R., C.S.S., J.C.V., R.P.R., and C.H. wrote the paper. activity was lost after digestion with Proteinase K, indicating that the antimicrobial substance is proteinaceous ( Fig. 1 B and C) . The producing strain was identified as a Bacillus based on biochemical tests in the API 50CHB and 20E kits. The strain was further characterized to the species level as B. thuringiensis using species-specific primers based on the gyrB gene that encodes the subunit B protein of DNA gyrase. No product was amplified with the B. cereus-or B. anthracis-specific primers. The possibility that the strain could belong to the anthracis species was excluded by the demonstration of inherent hemolytic activity, for which B. anthracis is generally deficient, and by the absence of the two large plasmids corresponding to the native plasmids pXO1 (181 kb) and pXO2 (96 kb) that harbor the machinery necessary to produce and regulate the anthrax virulence factors (20) . The strain, designated B. thuringiensis Dairy Products Centre Culture Collection (DPC) 6431 [Alimentary Pharmabiotic Centre Culture Collection (APC) 20], is unusual in that it produces a nontypical oval-shaped parasporal inclusion, and it was proven to not produce crystals or harbor a wide variety of cry genes. These inclusions would seem indicative of a newly described class of B. thuringiensis strains in which the inclusion is encoded by the slp gene and quickly degrades on cell lysis (21) . B. thuringiensis DPC 6431 (APC 20) is deposited with National Collection of Industrial and Marine Bacteria Patent Deposit (accession no. 41490).
Physical Characterization of the Bacteriocin from DPC 6431. The highest concentration of bacteriocin, designated thuricin CD, was detected during the late log phase and stationary phase of growth. Activity was stable during an extended stationary phase. The pH decreased during the exponential growth phase to ∼5.8 from an initial pH of ∼7.5; during the stationary phase, the pH rose again to ∼6.4 (Fig. S1 ). Microscopic examination throughout growth did not indicate a correlation between thuricin production and spore formation. Cell-free supernatants of thuricin were active throughout the pH range of 2-9 and heat stable up to 85°C. There was, however, a reduction in activity at 90°C and a complete loss of activity at 100°C after 15 min. Experimental details of the physical characterization of thuricin CD are described in SI Text.
Inhibition Spectrum of B. thuringiensis 6431. The cell-free supernatant (CFS) of B. thuringiensis 6431 was tested against a range of Gram-positive and Gram-negative bacteria using the well diffusion assay (WDA). Thuricin CD displayed a narrow spectrum of inhibition that was restricted mainly to spore-forming clostridia and bacilli. Within the Clostridium sp. tested, all C. difficile isolates, including the ribotypes commonly associated with C. difficile infection and most importantly, ribotype 027 (NAP1), were sensitive to the culture supernatants of DPC 6431 and exhibited large zones of inhibition. C. tyrobutyricum, C. lithuseburense, C. indolis, and C. perfringens were also inhibited. Among the other Gram-positive pathogens tested, only Listeria monocytogenes was sensitive to thuricin CD. A range of LAB was tested, but only L. fermentum was strongly inhibited by thuricin CD. None of the Bifidobacterium sp. tested were sensitive, including species commonly associated with the gastrointestinal tract. Thuricin CD showed no activity against any Gram-negative organisms tested, including Escherichia coli, Pseudomonas sp., Salmonella sp., and Bacteroides fragilis. The complete inhibition spectrum of B. thuringiensis DPC 6431 is outlined in Table S1 .
Characterization and Purification of Thuricin CD. Thuricin was purified from the CFS using both hydrophobic XAD-16 beads and extraction of the cell pellet with 70% propan-2-ol (pH 2.0) and subsequent purification of the combined fractions using C18 solid-phase extraction columns. The eluted material was further purified by RP-HPLC, resulting in two well-separated peaks at 34 and 41 min that eluted at ∼59% and ∼64% acetonitrile, respectively. MALDI-TOF MS analysis of the two distinct HPLC peaks revealed molecular masses of 2,763 and 2,861, respectively. These hydrophobic peptides were designated thuricin CD Trn-α (molecular mass = 2,763) and Trn-β (molecular mass = 2,861) (Fig. 1E) . Activity was present in both the CFS and propan-2-ol extract of the cell pellet, indicating that thuricin also adheres to the cell surface. Trn-β has activity at higher concentrations but is significantly enhanced by the presence of Trn-α; at low concentrations, both peptides are required for activity (Fig. 1D ).
Thuricin CD Activity Against C. difficile, L. monocytogenes, and Probiotic Cultures in Broth Cultures. Initial experiments determined the concentration of thuricin required to kill C. difficile in liquid culture; 100 arbitrary units (AU) thuricin/mL reduced the viable cells of C. difficile PCR ribotype 027 from ∼10 6 /mL to 0 within 3 h. The same concentration of thuricin reduced the cell numbers of L. monocytogenes by 1.5 log cycles, but cell numbers did not decrease further with time. The same concentration of thuricin had no effect on the viability of the commensal strains Lactobacillus casei 338 and B. lactis Bb12 in the same time period (Fig. S2 ). The addition of thuricin CD to logarithmically growing C. difficile caused a gradual reduction of OD600 nm; this decrease in OD was paralleled with a concomitant release of the intracellular enzyme acetate kinase into the growth medium, indicating a low level of cell lysis. In contrast, there was no increase in the concentration of acetate kinase in the control sample without thuricin (Fig. S3) .
The specific activity was determined by calculating the minimum inhibitory concentration (MIC) 50 using the purified Trn-α and Trn-β peptides where each of the peptides are titrated against each other, resulting in an isobologram plot. This shows (Fig. 2) that the MIC 50 of thuricin Trn-β (0.5 μM) is 10-fold less than Trn-α (5 μM) when present as individual peptides. However, the MIC 50 of Trn-β is reduced to 0.05 μM when combined with 0.025 μM Trn-α, indicating that the inhibitory activity of Trn-β is increased ∼100-fold when low concentrations of Trn-α are added. These results show that, under these conditions, the two peptides act synergistically in an optimal ratio of 2:1 (Trn-β: Trn-α) (Fig. S4) . Procedures for determining the specific activity of thuricin CD are described in SI Text. at equimolar concentrations showed that, in an ex vivo distal colon model, thuricin CD compared favorably with metronidazole, a common therapeutic agent used for treatment of CDAD. The effect of thuricin and metronidazole on the viability of C. difficile was significant relative to the control (P < 0.001 for thuricin CD and P < 0.05 for metronidazole) when data were analyzed for repeated measures using the SAS program (Fig. 2) .
Genetic Sequencing of the Putative Thuricin CD Operon. Edman degradation yielded incomplete peptide sequences, and therefore, the identification of the genetic determinants of thuricin CD was resolved by inverse PCR. Approximately 17 kb of contiguous sequence containing 25 putative ORFs were generated from seven overlapping PCR products. The structural genes trnB and trnA were identified as two complete ORFs, each consisting of 150 bp and 144 bp (Fig. 3A) . Although a promoter sequence could not be identified immediately upstream of the structural genes, both genes are preceded by canonical ribosomal binding sequences (RBS) embedded within a stretch of 21 identical nucleotides (AAAAATAAGGAGGAATTAATC). A short inverted repeat sequence occurs downstream of trnA, and a hairpin loop structure with typical features of a Rho-independent transcriptional terminator was predicted in this region (ΔG = −4.20 kcal/ mol). Such a terminator structure is not an unusual occurrence in bacteriocin gene clusters and may allow for low levels of a longer transcript encompassing downstream genes in a putative thuricin operon (22) .
The deduced amino acid sequences for both Trn-β (49 aa) and Trn-α (47 aa) share 45.3% sequence similarity (39.6% identity). Both peptides possess a conserved double-glycine (GG) motif, which is a common feature among bacteriocins that are synthesized as biologically inactive precursor peptides (prepeptides); however, unusually in this case, cleavage occurs between the GG residues rather than after the GG motif. The thuricin CD leaders are highly conserved (sequence similarity is 57.9% with 47.4% identity) and also share similar features with a number of other double glycine leaders in Class I [type-A(II)] and class II bacteriocins (22) . The thuricin CD leaders are both followed by 30 amino acid propeptide moieties that share 38.2% sequence similarity (35.3% identity). Interestingly, cysteine residues occur at positions +5, +9, and +13 in both peptides; Cys +5 is flanked by small hydrophobic amino acids Ala and Val, and those at positions +9 and +13 are coupled with variant small hydrophobic residues.
Upstream of the structural genes, two ORFs of 633 and 858 nucleotides were identified and designated trnF and trnG, respectively. A putative δ A promoter sequence was identified 88 nucleotides upstream from the RBS of trnF with a −10 region of TATAAT and a −35 region of TTGAAA. The putative TrnF (285 aa) and TrnG (210 aa) proteins contain regions with homology to ATP binding cassette (ABC) transport proteins (48% and 28% sequence identity, respectively). The TrnF protein is predicted to function as the C-terminal ATP-binding domain because of the presence of putative Walker motifs A and B. A perfect Walker A consensus motif beginning at Gly 33 was identified (GX 2 GXGKS/T), and a Walker B site (hhhD; h is any hydrophobic residue) was located in the region of amino acid 152 (23) The TrnG protein is predicted to function as the N-terminal hydrophobic integral membrane domain, including six transmembrane α-helices. Because two copies of each domain are required for functionality, it is expected that both proteins dimerize at the cytoplasmic membrane to form an active translocation complex (24) .
Two complete and overlapping ORFs designated trnC (1,521 bp) and trnD (1,245 bp) were identified 10 nucleotides downstream of the structural genes. Homology searches revealed that TrnC and TrnD belong to the radical S-adenosylmethionine (SAM or AdoMet) superfamily of proteins. These enzymes generally generate catalytic radicals through the reductive cleavage of AdoMet by combining SAM and an unusual iron sulfur cluster (4Fe-4S) (25) . A conserved single hallmark signature motif (CX 3 -C-X 2 -C) that coordinates the (4Fe-4S) cluster was identified within the N termini of both putative enzymes. TrnC exhibited sequence similarity to conserved domains of the Fe-S oxidoreductase arylsulfatase regulatory proteins (AslB), and TrnD had sequences similar to the MoaA family of molybdenum cofactor enzymes. Radical SAM enzymes rarely occur in bacteriocin gene clusters, but they are included in those of subtilosin A and propiocin F (26, 27) . Sequence alignments indicated that AlbA of subtilosin A exhibits only 19% and 17% identity to TrnC and TrnD, respectively, although AlbA exhibits some features of each individual thuricin CD protein.
Another ORF consisting of 1,194 nucleotides was identified immediately downstream and designated trnE. Homology searches revealed that TrnE belongs to the S41-type superfamily of C-terminal processing peptidases (CtpA) and has a putative intracellular function given the absence of a signal sequence. A perfect 18 nucleotide inverted repeat sequence was identified upstream of the TcdE protein, and a sequence corresponding to a Rho-independent transcriptional terminating hairpin loop was predicted in this region (ΔG = −19.90 kcal/mol).
MS/MS Sequencing and Exact Mass Determination of Trn-α and Trn-β.
The complete sequence of each thuricin CD peptide was determined using infusion MS/MS. The sequences matched with the genetic sequences of the peptides at all positions other than residues 21, 25, and 28 of both peptides (Fig. 3B) . At these positions, the MS/MS spectra indicated that the residues located at these positions in the mature peptides were two mass units lighter than expected. To confirm our findings, we determined the exact mass of Trn-α and Trn-β using MALDI Fourier transform ion cyclotron resonance MS. (Table S2) confirmed that residues 21, 25, and 28 of each peptide have lost two hydrogens from the predicted parent amino acid residue.
NMR Analysis of Trn-α and Trn-β. Carbon, nitrogen, and proton assignments for both peptides were determined using a suite of multidimensional NMR experiments. The chemical shifts of the backbone α-carbons and β-carbons were found using the HNCACB and CBCACONH experiments. It was immediately noted that the α-carbons of residues 21, 25, and 28 of both peptides have chemical shifts (Table S3 ) that are 15 ppm downfield of average values expected for unmodified residues (28) . These findings are consistent with an interpretation that an electronegative heteroatom such as sulfur is bonded to the α-carbon. Analysis of the 13 C HCCH-TOCSY and 13 C HSQC experiments confirmed that these α-carbons are fully substituted, having no attached α-protons. At the same time, the β-carbons of residues 21, 25, and 28 were found to have a normal substitution pattern with β-proton shifts (Table S3) close to expected values for unmodified residues (28). Long-range C HSQC-NOESY experiments are also consistent with a structure in which the sulfur atoms of cysteine side chains form linkages to the α-carbons of these modified residues. For Trn-α, it was found that the α-and β-protons of Cys13 show NOEs to the β-protons of Ser21. Similarly, the β-protons of Cys9 show NOEs to the γ-protons of Thr25. In addition, the amide proton of Thr28 shows NOEs to the β-protons of Cys5. This evidence shows the presence of sulfur to α-carbon linkage between Ser21 and Cys13, Thr25 and Cys9, and Thr28 and Cys5 in Trn-α (Fig. 4) . For Trn-β, the β-proton of Thr21
shows an NOE to the β-protons of Cys13, whereas the α-proton of Cys13 shows an NOE to the amide proton of Thr21. NOEs are also observed between the β-protons of Ala25 and the β-protons of Cys9. Likewise, NOEs appear between the β-protons of Cys5 and the β-protons of Tyr28. Taken together, the NOE data reflect the presence of sulfur to α-carbon thioether linkages between Thr21 and Cys13, Ala25 and Cys9, and Tyr28 and Cys5 in Trn-β (Fig. 4) .
Discussion
Screening over 30,000 isolates from fecal samples resulted in the detection of a single colony that inhibited the C. difficile overlay. The producing strain, identified as B. thuringiensis, is a sporeforming Gram-positive organism often used in agriculture to control insect pathogens. The newly identified bacteriocin, thuricin CD, is produced during the late log and stationary phases of growth but does not seem to be associated with sporulation. Thuricin CD was tested against a broad range of Grampositive and Gram-negative bacteria, and it was found to have a narrow spectrum of activity mainly restricted to spore forming Gram-positive bacteria. Notably, it inhibited a range of clinically significant C. difficile isolates, including the common ribotypes associated with outbreaks and most importantly, the hypervirulent PCR ribotype 027 NAP1. Moreover, in an ex vivo model of the distal colon, thuricin CD compares very favorably with metronidazole, the first antibiotic of choice for the treatment of CDAD. Its effect on C. difficile in a simulated colon environment would suggest that thuricin CD may have applications as a therapeutic for CDAD after its biological activity is protected for targeted delivery to the colon. We have shown that thuricin CD is a two-component bacteriocin with each peptide displaying activity at concentrations of 5 μM and 0.5 μM for Trn-α and Trn-β, respectively. However, the activity is greatly enhanced when both peptides are present, reducing the MIC 50 to nanomolar values with an optimal 1:2 ratio of Trn-α:Trn-β. Thuricin CD significantly reduces cell numbers of C. difficile ribotype 027 (NAP 1) at low concentrations (100 AU/mL). A potential problem associated with using traditional broad-spectrum antibiotics to treat CDAD is that these drugs will cause perturbations in the gut flora, a phenomenon that is likely to impede recovery and may even promote a recurrence of the disease. We have also shown that the broad-spectrum bacteriocin lacticin 3147 inhibits beneficial Gram-positive organisms in the gut (18) . However, thuricin CD does not kill Lb. casei 338 or B. lactis Bb12, species generally regarded as contributing to gut health, at concentrations potent enough to kill C. difficile. When thuricin CD is added to logarithmically growing cells, limited cell leakage occurs with a slow reduction in OD accompanied by release of the intracellular enzyme acetate kinase. This differs from the effect of the two-component lantibiotic lacticin 3147, which shows rapid lysis of the cells shortly after addition of the peptides. This difference, combined with the much narrower spectrum of activity for thuricin CD, suggests that the mode of action is different to that of lacticin 3147 (18) .
Genetic sequencing of the putative thuricin CD operon afforded insight into the mechanisms responsible for the biosynthesis and cellular export of the two peptides. TrnF and G are likely to constitute an ABC transporter responsible for the export of the bacteriocin from the cytoplasm, whereas TrnC and D are suitable candidates to be involved in the formation of the unusual cysteine/α-carbon linkages. As a member of the S41 superfamily of C-terminal processing peptidases, TrnE is not likely to be involved in signal sequence cleavage and may have an immunity function. Trn-β is similar to a partially sequenced twocomponent bacteriocin produced by B. thuringiensis 439 (13) . It was reported that the B439 bacteriocin produced two peptides with molecular masses of 2,919 and 2,803 that did not act synergistically and did not inhibit Clostridium sp. Our analysis of B. thuringiensis B439 has confirmed that the strain possesses structural genes with nucleotide sequences identical to those of the thuricin CD producer; the strain produces two peptides of identical mass to thuricin CD and is active against C. difficile.
NMR analysis of Trn-α and Trn-β sheds light on the nature of the posttranslational modifications at residues 21, 25, and 28. Full assignment of the peptide backbones and side chains revealed that the α-proton on each of these modified residues is absent, whereas all of the β-protons are present. In addition, the α-carbon chemical shifts of these residues are significantly downfield from expected values for unmodified residues (28) . Because these chemical shifts occur between 70 and 80 ppm, it suggests that a heteroatom, such as sulfur, is attached to the α-carbon. Examination of long-range 1 H-1 H NOEs indicates that through-space interactions exist between Cys13 and residue 21, Cys9 and residue 25, and Cys5 and residue 28 in both peptides. As a consequence, we conclude that each peptide features three sulfur to α-carbon thioether linkages between the cysteine side chains and the α-carbons of the modified residues, contrary to our initial hypotheses that residues 21, 25, and 28 are oxidized to carbonyl-containing residues or dehydro residues. The presence of these sulfur to α-carbon bridges initially seems to contradict the results from MS that suggest unmodified cysteines and dehydro residues at positions 21, 25, and 28. However, the proposed structures are the observed 6 daltons lighter than predicted from the parent amino acid sequences determined by genetic sequencing. It is apparent that, during the ionization of the peptides by MALDI or infusion, the thioether linkages break with elimination of a neighboring amide proton (Fig. S7) to give free cysteine residues at positions 5, 9, and 13 and oxidized (dehydro) residues at positions 21, 25, and 28.
There has been only one other report of sulfur to α-carbon linkages in a naturally occurring peptide, the antimicrobial subtilosin A (29) . Subtilosin A is a 35-residue single-component bacteriocin that is backbone cyclized between its N and C termini. In addition to this backbone cyclization, it also features three thioether bridges, whereby the side chains of its three cysteine residues attach to the α-carbons of a threonine and two phenylalanine residues. Inspection of the NMR shifts found for the residues of thuricin CD with those of subtilosin A show that the α-linked residues of both bacteriocins have comparable chemical shifts, as do the cysteine residues. A SAM-containing enzyme with slight homology to the SAM-containing enzyme thought to be responsible for forming the thioether linkages in subtilosin A was found on the thuricin operon. We have found that subtilosin A does not inhibit C. difficile. The efficacy of thuricin CD against clinical C. difficile isolates, especially the hypervirulent PCR ribotype 027, makes this bacteriocin an exciting subject of study, both for its structural features and its potential as a therapeutic agent. Because thuricin CD is a twopeptide bacteriocin that features sulfur to α-carbon linkages, further investigation of the structure-activity relationships between the two peptides may reveal a unique mechanism of action for thuricin CD against its target bacteria. Studies are currently underway to determine the complete 3D structure of each peptide in isolation and in the presence of the other component. The isolation and characterization of thuricin CD may represent a structural class of bacteriocins as well as potentially providing a treatment for CDAD.
Materials and Methods
Bacterial Strains Used. C. difficile ATCC 43593 was used to isolate antimicrobial agent producing bacteria from mixed populations in fecal samples. C. difficile R1/NAP1/027, Lactobacillus casei 338, Bifidobacterium lactis Bb12, and Listeria monocytogenes NCTC 5348 were used for bacteriocin sensitivities in time-kill studies. C. difficile ATCC 43593 and Bacillus firmus LMG 7125 t were used for determination of activity of thuricin by well diffusion assay. A full list of the target organisms and their sources that were used for determination of the spectrum of inhibition of the bacteriocin-producing cultures is outlined, together with the media and growth conditions, in Table  S1 . B. cereus NCIMB 700577 and B. thuringiensis NCIMB 701157 were used as positive controls for the PCR using gyrB primers.
Isolation of Bacteriocin-Producing Cultures. Fecal samples from both diseased and healthy individuals were received in the laboratory and frozen at −80°C. On the day of analysis, samples were thawed at room temperature, mixed with equal volumes of absolute ethanol, and allowed to stand at room temperature for ∼30 min. Samples were subsequently serially diluted in anaerobic diluent, 100 μL spread on the surface of Wilkens Chargrin anaerobic agar (WCAA), and grown for 5 days at 37°C in an anaerobic chamber. Colonies that developed were overlaid with ∼10 mL of reinforced Clostridium agar (RCA) inoculated at 1.25% with a log-phase culture of C. difficile. The plates were incubated for another 18 h and inspected for zones of inhibition of the overlaid culture. Colonies showing a clear zone of inhibition were subcultured onto fresh WCAA having first removed the agar overlay using a sterile scalpel blade. Approximately 30,000 colonies were screened, and one colony showing potent antimicrobial activity against the overlaid C. difficile strain was purified and stocked at −80°C on Microbank Beads and designated as DPC6431 (APC 20) ; the inhibitory substance produced was designated thuricin CD. 
